Download video

Assessing the role of sunvozertinib in pretreated NSCLC and in potential first-line usage

43 views

VJOncology

4 months ago

Assessing the role of sunvozertinib in pretreated NSCLC and in potential first-line usage

Assessing the role of sunvozertinib in pretreated NSCLC and in potential first-line usage

Assessing the role of sunvozertinib in pretreated NSCLC and in potential first-line usage
0:57
Assessing the role of sunvozertinib in pretreated NSCLC and in potential first-line usage
by VJOncology
WU-KONG1: sunvozertinib in NSCLC with EGFR exon 20 insertion mutations
3:51
WU-KONG1: sunvozertinib in NSCLC with EGFR exon 20 insertion mutations
by VJOncology
REZILIENT1: zipalertinib, a novel EGFR TKI, in NSCLC with ex20ins mutations
2:43
REZILIENT1: zipalertinib, a novel EGFR TKI, in NSCLC with ex20ins mutations
by VJOncology
Sunvozertinib \& EGFR Exon 20 Insertion NSCLC-Leading Developments \& Current Questions in Lung Cancer
9:15
Sunvozertinib \& EGFR Exon 20 Insertion NSCLC-Leading Developments \& Current Questions in Lung Cancer
by GRACE - Global Resource for Advancing Cancer Education
Treatment Options: Newly Diagnosed EGFR+ NSCLC
3:22
Treatment Options: Newly Diagnosed EGFR+ NSCLC
by Targeted Oncology
Current and novel treatment approaches for first-line EGFR-m NSCLC
1:09
Current and novel treatment approaches for first-line EGFR-m NSCLC
by VJOncology
Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20
1:32
Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20
by Targeted Oncology
Evaluating the Role of EGFR Mutations in the Treatment of Advanced NSCLC
1:14
Evaluating the Role of EGFR Mutations in the Treatment of Advanced NSCLC
by Targeted Oncology
Osimertinib Tablet Explained: Uses, Dosage, Mechanism, Side Effects \& Expert Advice | MediInsights
3:35
Osimertinib Tablet Explained: Uses, Dosage, Mechanism, Side Effects \& Expert Advice | MediInsights
by MediInsights
Precision Oncology in Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way
59:19
Precision Oncology in Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way
by PeerView Oncology
Assessing the clinical characteristics of lung adenosquamous carcinoma
1:10
Assessing the clinical characteristics of lung adenosquamous carcinoma
by VJOncology
Emerging role of ADCs in EGFR-mutated non-small cell lung cancer
1:13
Emerging role of ADCs in EGFR-mutated non-small cell lung cancer
by VJOncology
2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2
20:34
2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2
by Total Health | Oncology
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC
6:28
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC
by Future Science Group
Evaluating first-line therapies for EGFR-mutated NSCLC in 2024
1:51
Evaluating first-line therapies for EGFR-mutated NSCLC in 2024
by VJOncology
Assessing the role of consolidation therapy for EGFR-mutant NSCLC
2:39
Assessing the role of consolidation therapy for EGFR-mutant NSCLC
by VJOncology
Assessing EFGR TKIs in patients with wild-type EFGR NSCLC
0:48
Assessing EFGR TKIs in patients with wild-type EFGR NSCLC
by VJOncology
First-Line Therapy in the Patient with EGFR-Mutant Lung Cancer
6:56
First-Line Therapy in the Patient with EGFR-Mutant Lung Cancer
by OncLive
Selecting a First-Line EGFR Inhibitor in NSCLC
6:46
Selecting a First-Line EGFR Inhibitor in NSCLC
by OncLive
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer
3:31
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer
by ecancer